TOKYO, JAPAN - July 4, 2018 - Terumo Corporation (TSE: 4543) today announced shipping delays for products from its Ashitaka Factory in Shizuoka, Japan. This factory produces certain cardiovascular products. No other Terumo factories are affected by this issue.
While Terumo was pursuing enhancements of its manufacturing capabilities at the Ashitaka Factory, the company discovered that there were challenges in the procedure that optimizes the sterilization process. Shipments of certain products from this factory have been placed on hold in late May, based on its internal rules.
Terumo is gradually resuming shipments as it confirms the procedure. The company is aiming to resume full shipping by mid-August.
Terumo is now assessing the financial impact and will disclose findings as they are confirmed. The company plans to provide updates on the progress of this matter at the 1st quarter financial results announcement on August 8th.
Based on the company's corporate mission, "Contributing to Society through Healthcare," Terumo is making every effort to minimize disruption of product supply.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.